Core Viewpoint - A securities class action lawsuit has been filed against BioAge Labs, Inc. for alleged misleading statements related to its IPO and clinical trials [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased BioAge stock during the IPO period around September 26, 2024 [1]. - The lead plaintiff deadline for the lawsuit is set for March 10, 2025 [1][3]. Group 2: Allegations Against Defendants - The complaint alleges that BioAge's registration statement and prospectus contained false or misleading statements regarding the STRIDES Phase 2 trial for azelaprag [2]. - Specific allegations include failure to disclose the potential for liver transaminitis in previous clinical trials and preclinical studies [2]. - It is claimed that BioAge misrepresented the safety concerns and expected outcomes of the STRIDES clinical trial, leading to materially false statements about the company's business and prospects [2]. Group 3: Lead Plaintiff Process - Investors can seek to be appointed as a lead plaintiff representative by the March 10, 2025 deadline, or they can choose to remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select counsel for the litigation [3]. Group 4: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm encourages affected BioAge investors to contact them for more information regarding the lawsuit [4].
BioAge Labs, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds BioAge Labs, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit